BioCryst Pharmaceuticals BCRX Business Segments — Cost of product sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's business segments — cost of product sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's business segments — cost of product sales?
- BioCryst Pharmaceuticals (BCRX) reported business segments — cost of product sales of $5.38M in Q1 2026.
- How has BioCryst Pharmaceuticals's business segments — cost of product sales changed year-over-year?
- BioCryst Pharmaceuticals's business segments — cost of product sales increased by 17.7% year-over-year, from $4.57M to $5.38M.
- What is the long-term trend for BioCryst Pharmaceuticals's business segments — cost of product sales?
- Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's business segments — cost of product sales has grown at a 43.9% compound annual growth rate (CAGR), from $6.41M to $19.08M.
- What does business segments — cost of product sales mean?
- Includes the direct costs associated with manufacturing, packaging, and distributing the products sold by the segment. Monitoring this helps evaluate the segment's production efficiency and the impact of manufacturing scale on gross margins.